Cherwell Launches Refreshed Website for Cleanroom Microbiology Solutions
Cherwell Laboratories, specialists in cleanroom microbiology solutions for the pharmaceutical and related industries, has launched a refreshed website. Designed to make it even easier for customers to find relevant product information, expert advice and technical information, the updated and fully responsive website also provides access to example product applications, testimonials and industry news via tablets and smartphones.
“Over the past 40 years, we have developed a reputation for offering expert technical advice and support,” commented Andy Whittard, Managing Director, Cherwell Laboratories. “To make this information more accessible, our refreshed website includes a number of new features such as frequently asked questions, a glossary and a Cherwell blog to ensure we can keep our customers up-to-date on the latest company and industry developments.”
Cherwell’s website provides information on their range of cleanroom microbiology products, developed to meet the specific requirements of the industrial microbiology sector. The product range incorporates Redipor prepared microbiological media for environmental monitoring and process validation, SAS microbial air samplers for active environmental monitoring in a variety of applications and the Mar Cor range of cold sterilants and Dry Fog technology for cleanroom bio-decontamination. In addition to product specific information, the website also offers access to regulatory updates and industry events.
“We were keen to ensure that our contact details remain very visible as we are always happy to discuss applications and solutions with new users,” continued Andy Whittard. The new website also has easier access to downloadable content, newsletter sign up and links to Cherwell’s growing network of European distributors.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.